Cover Image

Ranibizumab Port Delivery System in Neovascular Age-Related Macular Degeneration: Where Do We Stand? Overview of Pharmacokinetics, Clinical Results, and Future Directions

The ranibizumab (RBZ) port delivery system (PDS) is a device designed to continuously deliver RBZ in the vitreous chamber for the treatment of neovascular age-related macular degeneration (nAMD). It is implanted during a surgical procedure and can provide sustained release of the medication for seve...

Full description

Saved in:

Bibliographic Details
Main Authors:	Matteo Mario Carlà (Author), Maria Cristina Savastano (Author), Francesco Boselli (Author), Federico Giannuzzi (Author), Stanislao Rizzo (Author)
Format:	Book
Published:	MDPI AG, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
by: Wang LP, et al.
Published: (2018)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021)

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab
by: Pablo Almuiña-Varela, et al.
Published: (2024)

Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019)

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2024)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
by: Lorenzo Ferro Desideri, et al.
Published: (2023)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
by: Chen Y, et al.
Published: (2012)

EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration
by: Lu Cheng, et al.
Published: (2021)

Profile of conbercept in the treatment of neovascular age-related macular degeneration
by: Lu XM, et al.
Published: (2015)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021)

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration
by: Panos GD, et al.
Published: (2013)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
by: Jing Wang, et al.
Published: (2021)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
by: Pengxiang Zhou, et al.
Published: (2021)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
by: Yang S, et al.
Published: (2016)

Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics
by: Kim Ivana K, et al.
Published: (2011)

Application of Artificial Intelligence Models to Predict the Onset or Recurrence of Neovascular Age-Related Macular Degeneration
by: Francesco Saverio Sorrentino, et al.
Published: (2024)

Hypertensive disorders of pregnancy increase the risk of developing neovascular age-related macular degeneration in later life
by: Karen Curtin, et al.
Published: (2019)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
by: Hussain RM, et al.
Published: (2021)

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
by: Wissam Aljundi, et al.
Published: (2024)

Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration
by: Ryosuke Motohashi, et al.
Published: (2018)

Use of ranibizumab for the treatment of subretinal neovascularization in pathologic myopia: a prospective study
by: О.M. Blavatska, et al.
Published: (2016)

Diabetes Care in Iran: Where We Stand and Where We Are Headed
by: Sina Noshad, et al.
Published: (2016)

Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018)

Violence: where do we stand?
by: Wasantha Gunathunga
Published: (2001)

Where are we standing in occupational cardiology?
by: Uğur Nadir Karakulak
Published: (2015)

Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study
by: Anna-Maria Kubin, et al.
Published: (2024)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022)

Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Yinchen Shen, et al.
Published: (2022)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022)

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration
by: Li W, et al.
Published: (2016)

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
by: A. F. Yusupov, et al.
Published: (2024)

Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization
by: Petrou P, et al.
Published: (2013)

Early and Late Infections in Newborns: Where Do We Stand? A Review
by: Francesca Cortese, et al.
Published: (2016)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022)

Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration
by: Joanna Dolar-Szczasny, et al.
Published: (2021)

The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Xinyu Zhao, et al.
Published: (2021)

Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment
by: Irmela Mantel, et al.
Published: (2020)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
by: Balázs Horváth, et al.
Published: (2022)

Chronic autoimmune urticaria : Where we stand ?
by: Goh C, et al.
Published: (2009)